Gemtuzumab Ozogamicin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00056 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 19 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Richter syndrome | KG + DL |
| 2 | bulbar polio | KG + DL |
| 3 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 4 | metastatic neoplasm | KG + DL |
| 5 | malignant spiradenoma | KG + DL |
| 6 | 5q35 microduplication syndrome | KG + DL |
| 7 | neuralgic amyotrophy | KG + DL |
| 8 | amyotrophic neuralgia | KG + DL |
| 9 | acute lymphoblastic/lymphocytic leukemia | KG + DL |
| 10 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | KG + DL |
| 11 | acute myeloid leukemia and myelodysplastic syndromes related to radiation | KG + DL |
| 12 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 13 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 14 | polyclonal hypergammaglobulinemia | KG + DL |
| 15 | familial thrombocytosis | KG + DL |
| 16 | myelodysplastic/myeloproliferative disease | KG + DL |
| 17 | monoclonal paraproteinemia disease | KG + DL |
| 18 | acute panmyelosis with myelofibrosis | KG + DL |
| 19 | reactive thrombocytosis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.